20/20 GeneSystems

20/20 GeneSystems

Growth Stage

Diagnostic Testing for COVID-19 & Cancer


Raised this Round: Raised: $232,704

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Convertible Note


Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Rockville, Maryland

Business Type


20/20 GeneSystems, with a valuation of $58.4 million, is raising funds on StartEngine. It is a diagnostics company with a successful track record in cancer detection with its AI-powered multi-cancer blood test, OneTest. The company has also launched CoronaCheck, its FDA-authorized antibody lab test for COVID-19 antibodies. The business reported revenues of $9 million in 2021, a 300% increase over 2020 revenues. Jonathan Cohen founded 20/20 GeneSystems in 2000. The current crowdfunding campaign has a minimum target of $9,995.40 and a maximum target of $4,999,995. The campaign proceeds will be used to expand the portfolio of tests and grow revenues.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 08/15/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
20/20 GeneSystems 09/03/2024 Wefunder $69,859,000 $158,269 Equity - Preferred Active RegCF
20/20 GeneSystems 12/20/2022 StartEngine $58,400,000 $232,704 Convertible Note Funded RegCF
20/20 GeneSystems 06/26/2021 StartEngine $38,500,000 $2,903,017 Equity - Preferred Funded RegA+
20/20 GeneSystems 10/31/2020 SeedInvest $38,500,000 $3,792,229 Equity - Preferred Funded RegA+
20/20 GeneSystems 12/13/2017 Microventures $23,000,000 $1,064,807 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

20/20 GeneSystems offers an affordable blood test that screens for multiple types of cancer. It also has access to the medical records of more than 200,000 patients with known cancer outcomes. Its testing technology and machine learning algorithms are innovative — but it’s not clear if there’s enough market demand for its product.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
20/20 GeneSystems on StartEngine 2022
Platform: StartEngine
Security Type: Convertible Note
Valuation: $58,400,000

Follow company

Follow 20/20 GeneSystems on StartEngine 2022

Buy 20/20 GeneSystems's Deal Report

Warning: according to the close date for this deal, 20/20 GeneSystems may no longer be accepting investments.

20/20 GeneSystems Deal Report

Get KingsCrowd’s comprehensive report on 20/20 GeneSystems including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether 20/20 GeneSystems is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the 20/20 GeneSystems deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge